News on lab-developed tests and emerging diagnostic technologies.
Last month, the company announced two transactions that it said would enable it to regain compliance with the Nasdaq's listing requirement.
A study questioned the cost-effectiveness of the test in clinically low-risk women, but the firm stressed that a wealth of evidence continues to support its use under current guidelines.
The firm plans to add more oncology tests, NIPTs and newborn screening assays through in-house development and partnerships with third-party assay makers.
Onkos Molecular Diagnostics is looking for a US partner to commercialize its 11 miRNA-based mir-THYpe test, which it believes offers advantages over tests on the market.
The firm missed the consensus Wall Street estimate on the bottom line, even as its ePlex analyzer Q4 revenues more than doubled year over year to $12.1 million.
